News | May 18, 2025
Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The change of name has been carried on pursuant to the Scheme of Amalgamation
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The closing of the Block Acquisition is now expected to be completed by Q3 2025
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The European regulator will conduct a re-inspection of the facility to verify the compliance
Subscribe To Our Newsletter & Stay Updated
